Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
• Age ≥18 years
• Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
• At increased risk of postoperative complications based on ≥1 of the following:
‣ Age ≥65 years
⁃ eGFR \<45 ml/min/1.73m2
⁃ Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery
⁃ Diabetes mellitus and urine albumin-to-creatinine ratio \>30 mg/g creatinine
⁃ Peripheral arterial disease
⁃ Anemia, defined as hemoglobin \<10 g/dl
⁃ Prior cardiac surgery